Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. [electronic resource] by
- Varghese, Abraham M
- Howard, Dena R
- Pocock, Christopher
- Rawstron, Andy C
- Follows, George
- McCarthy, Helen
- Dearden, Claire
- Fegan, Christopher
- Milligan, Donald
- Smith, Alexandra F
- Gregory, Walter
- Hillmen, Peter
Producer: 20170608
In:
British journal of haematology vol. 176
Availability: No items available.
|
|
10.
|
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. [electronic resource] by
- Hillmen, Peter
- Cohen, Dena R
- Cocks, Kim
- Pettitt, Andrew
- Sayala, Hazem A
- Rawstron, Andy C
- Kennedy, Daniel B
- Fegan, Christopher
- Milligan, Don W
- Radford, John
- Mercieca, Jane
- Dearden, Claire
- Ezekwisili, Raphael
- Smith, Alexandra F
- Brown, Julia
- Booth, Gillian A
- Varghese, Abraham M
- Pocock, Christopher
Producer: 20110512
In:
British journal of haematology vol. 152
Availability: No items available.
|